Davis Polk advised the underwriters in connection with an initial public offering of 15,972,221 shares of common stock of Denali Therapeutics Inc., including shares sold pursuant…
Denali Therapeutics Inc. $287 Million Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 15,972,221 shares of common stock of Denali Therapeutics Inc., including shares sold pursuant…